ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z
  • Abstract Number: 1254
    Ultra High‐Frequency Ultrasound of Labial Salivary Glands in Primary Sjögren’s Syndrome: A Promising Tool to Identify Lymphoproliferative Lesions in Unusual Sites
  • Abstract Number: 2230
    Ultra-Rare Genetic Variation in Relapsing Polychondritis: A Whole-Exome Sequencing Study
  • Abstract Number: 1790
    Ultrasound Diagnosis of Calcium Pyrophosphate Crystal Deposition: Which Sites Should Be Scanned?
  • Abstract Number: 1233
    Ultrasound Is Reliable in the Assessment of Muscle Echogenicity in Patients with Rheumatic Diseases: Results of a Multicenter International Web-based Study
  • Abstract Number: 2229
    Ultrasound Localization Microscopy as a New Tool for Takayasu’s Arteritis Activity Assessment, a Deep Insight Within Carotid Wall Inflammation
  • Abstract Number: 0468
    Ultrasound Wall Thickness in the Differential Diagnosis of Atherosclerosis and Large Vessel Giant Cell Arteritis
  • Abstract Number: 0798
    Uncovering the Relationship Between COVID-19 Outcome Severity and Rheumatic Disease
  • Abstract Number: 1919
    Underdiagnosis and Undertreatment of Knee Osteoarthritis in Persons with Type 2 Diabetes: A Cross-sectional Study
  • Abstract Number: 0669
    Understanding How Type I Interferon Modulates Langerhans Cell ADAM17 to Promote Photosensitivity in Lupus
  • Abstract Number: 2206
    Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
  • Abstract Number: 0729
    Understanding the Practice and Process of Patient Reported Outcome Measures Collection in North American Pediatric Rheumatology Clinics: A Survey of the Pediatric Rheumatology-Care and Outcomes Improvement Network
  • Abstract Number: 2076
    Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus
  • Abstract Number: 0955
    Unfavorable Pregnancy Outcome Is Significantly Associated with Corticosteroid Exposure During Pregnancy in Women with RA: Analysis of the Prospective GR2 Cohort
  • Abstract Number: 1626
    Unique Biological Profile of Germinal Centres Within Tertiary Lymphoid Structures in the Salivary Glands of Patients with Sjögren’s Syndrome
  • Abstract Number: 0744
    University of North Carolina and Piedmont Health Collaborative Tele-Rheumatology Project to Optimize Rural Health Specialty Access
  • Abstract Number: 2197
    Unmet Need in Systemic Lupus Erythematosus (SLE) Therapy: High Corticosteroid Use and Poor Adherence and Persistence to SLE Treatments in the US
  • Abstract Number: 0827
    Unpublished Clinical Trials of Major Rheumatic Diseases
  • Abstract Number: 1823
    Unsupervised Cluster Analysis of Clinical and Ultrasound Features Reveals Unique Gout Subtypes: Results from the Egyptian College of Rheumatology (ECR)
  • Abstract Number: 0909
    Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs
  • Abstract Number: 1127
    Unsupervised Clustering Analysis of the Serum Proteome Identifies Systemic Sclerosis Patients with Distinctive Clinical Features
  • Abstract Number: 1473
    Unsupervised Clustering of Lupus Patient-Reported Outcome Data Identifies Patient Groups with Differences in SLEDAI and Physician Global Assessment
  • Abstract Number: 0425
    Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis – Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2)
  • Abstract Number: 0192
    Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
  • Abstract Number: 1388
    Updating and Validating the Rheumatic Disease Comorbidity Index to Incorporate ICD-10 Diagnostic Codes
  • Abstract Number: 1271
    Uptake of Rheumatology-Specific Quality Measures Submitted to National Pay-for-Performance Programs: An Analysis of Participants in the RISE Registry
  • Abstract Number: 1811
    Urate Lowering Therapy Initiation in Hospitalized Patients with Acute Gout Flares
  • Abstract Number: 1828
    Urate-lowering Therapy Reduces Non-Episodic Foot Pain in Patients Who Fail to Meet ACR/EULAR 2015 Gout Classification Criteria: An Effect Predicted by Ultrasound
  • Abstract Number: 1859
    Urinary Beta-2 Microglobulin Is a Sensitive Prognostic Marker in Dermatomyositis Patients with Interstitial Lung Disease Positive for Anti-MDA-5 Antibody
  • Abstract Number: 1478
    Urine ALCAM Is a Strong Predictor of Lupus Nephritis
  • Abstract Number: 1135
    Urine Proteomics Implicate Complement C3 and Factor I in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
  • Abstract Number: 1359
    Usability and Acceptability of a Digital Behavioral Therapy for the Management of Fibromyalgia
  • Abstract Number: 1210
    Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis
  • Abstract Number: 1533
    Use of Body Mass Index in Prediction of Interstitial Lung Disease Related to Systemic Sclerosis Revealed by Decision Trees
  • Abstract Number: 0928
    Use of Disease Modifying Anti-rheumatic Drugs and Risk of Multiple Myeloma in US Veterans with Rheumatoid Arthritis
  • Abstract Number: 0969
    Use of Gonadotropin-releasing Hormone Agonists for Ovarian Preservation in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus: A Meta-analysis
  • Abstract Number: 1643
    Use of Oral Analgesics and Risk of Comorbidities in Osteoarthritis: Findings from Primary Care Settings in the UK
  • Abstract Number: 0745
    Use of Telemedicine in Patients with Systemic Lupus Erythematosus in a Publicly Funded Hospital System
  • Abstract Number: 0834
    Use of the Routine Assessment of Patient Index Data 3 (RAPID3) Questionnaire in the Assessment of Chronic Lower Back Pain
  • Abstract Number: 1057
    Usefulness of REVEAL 2.0 Score as a Prognosis Tool of All-Cause Pulmonary Hypertension in Systemic Sclerosis Patients: A Multicentric Study
  • Abstract Number: 1978
    Using Administrative Health Data to Construct a Frailty Index as a Measure of Susceptibility to Adverse Health Outcomes Among Individuals with Rheumatoid Arthritis
  • Abstract Number: 1519
    Using Galacetin-3 (Gal-3) and Cardiotrophin-1 (CT-1) for Early Detection of Primary Heart Involvement in Systemic Sclerosis as Seen on Cardiac MRI
  • Abstract Number: 1448
    Utility of Digital Signals and Patient Reported Data Gathered in a Decentralized Study to Predict SLE Patient-Reported Flares
  • Abstract Number: 0474
    Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients
  • Abstract Number: 0725
    Utility of Repeat Extractable Nuclear Antigen Antibody Testing- a Retrospective Audit
  • Abstract Number: 0463
    Utilization of a Giant Cell Arteritis Fast-Track Program Independent of Ultrasound at a Single Center
  • Abstract Number: 0080
    Utilization of Biologic and Targeted Disease Modifying Antirheumatic Therapy in Patients with Rheumatoid Arthritis and Breast Cancer
  • Abstract Number: 1764
    Utilization of Electronic Health Record Data to Evaluate the Impact of Urban Environment on Risk of Systemic Lupus Erythematosus Symptoms
  • Abstract Number: 0064
    Utilization of Preventive Services in a Systemic Lupus Erythematosus Population-Based Cohort: A Lupus Midwest Network Study
  • Abstract Number: 1043
    Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis
  • Abstract Number: 1159
    Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center
Jump to:  View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology